Hepatocellular carcinoma
Conditions
Interventions
Sponsors
Kitasato University Scool of Medicine, Department of Gastroenterology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with HCC that are histologically or clinically confirmed, unsuitable for resection or locoregional therapy. 2) TNM stage 2 or 3. 3) Patients with HCC that show arterial phase enhancement. 4) Child-Pugh class A or B. 5) History of treatment for HCC within previous 3 months. 6) A life expectancy of 3 months or more. 7) Performance status score (ECOG) of 2 or less. 8) Patients who fulfill of the inclusion criteria below. 1. WBC >=2000/mm3 2. PLT >=50000/mm3 3. Hb >=8.0g/d/dl 4.T.Bil <=3.0mg/dl 5. PT >=40% 6. AST, ALT <=5 x the upper limit of the normal range. 7. Cr <=the upper limit of the normal range. 9) Patients who were provided written informed consent.
Exclusion criteria
Exclusion criteria: 1) Vascular invasion or bile duct invasion. 2) Extrahepatic metastasis. 3) Major arterioportal shunt in the liver. 4) Combination with locoregional therapy. 5) Hepatic encephalopathy or refractory ascites. 6) Adjuvant therapy with IFN, Vit A or anti cancer drug. 7) Patients who have medical history of hypersensitivity of iodine or contrast media. 8) Patients who have severe thyroid disease. 9) Patients who are pregnant, lactating or are suspected to be pregnant. 10) Patients who are concluded to be inappropriate to participate in this study by their physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to progression | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate Safety Overall survival | — |
Countries
Japan
Contacts
Public ContactYusuke Okuwaki
Kitasato University East Hospital Department of Gastroenterology
Outcome results
None listed